Alnylam Pharmaceuticals Leads Healthcare Sector in Q3 Earnings Surprises
As the third-quarter earnings season concludes, several healthcare companies have reported earnings-per-share (EPS) results that significantly outperformed Wall Street consensus estimates. This trend indicates localized strength across diverse sub-sectors, including biotechnology, pharmaceuticals, diagnostics, and managed care. Alnylam Pharmaceuticals emerged as the top performer with a substantial $14.01 EPS surprise. Other notable outperformers include Edgewise Therapeutics and GRAIL, demonstrating that positive earnings momentum is present across both specialized biotech firms and broader healthcare service providers.

Tickers: $ALNY $GRAL $LLY $REGN
Topics: biotechnology earnings per share healthcare earnings pharmaceuticals
Read the full article at Seeking Alpha
Part of the story Reliance leads materials stocks with biggest Q3 earnings surprise (3 articles)